Board of Advisors

Scientist in laboratory looking through a microscope

Working together to prevent blindness

Odylia Therapeutics is a 501(c)(3) corporation combining the expertise and experience of our founders, board members, and partner organizations to fill a unique void in moving ultra-rare inherited retinal diseases from science to humans. Our organization focuses on those diseases that would typically have limited commercial appeal and would be neglected, even though the science is available to make significant progress.

Board of Directors

Luk H. Vandenberghe, Ph.D. of Odylia Therapeutics profile picture

Luk Vandenberghe, PhD
Associate Professor, Harvard Medical School
Director, Grousbeck Gene Therapy Center
Massachusetts Eye and Ear

Scott Dorfman, CEO and co-founder of Odylia Therapeutics

Scott Dorfman, BBA
CEO, Odylia Therapeutics

Mathew Pletcher, PhD. Assistant professor, Harvard Medical School, Director Grousbeck Gene Therapy Center Massachusetts Eye and Ear profile picture

Matthew Pletcher, PhD
RDH12 Fund for Sight

Emil

Emil Kakkis, MD, PhD
President and Founder
Ultragenyx Pharmaceutical Inc

Advisory Board

Eric A. Pierce, M.D., Ph.D., Director of the Inherited Retinal Disorders Service at Massachusetts Eye and Ear

Eric Pierce, MD, PhD
Director, Ocular Genomics Institute
Harvard Medical School
Director, Inherited Retinal Disorders Services
Massachusetts Eye and Ear

Joy Cavagnaro profile picture

Joy Cavagnaro, PhD
President, Access Bio

jean-bennet cropped

Jean Bennett, MD, PhD
Professor, Perelman School of Medicine
University of Pennsylvania

Alberto Auricchio, Ph.D., Associate Professor of Medical Genetics at Federico II University Napoli and Principal Investigator, TIGEM

Alberto Auricchio, PhD
Associate Professor of Medical Genetics
“Federico II” University Napoli
Principal Investigator, TIGEM

Alan M. Spiro, JD, PhD profile picture

Alan Spiro, BA, PhD, JD
Partner, ExSight Ventures

C0135927 Greg Robinson - NightstaRX

Gregory Robinson, PhD
Chief Scientific Officer, Akouos

Founding Members

Luk H. Vandenberghe, Ph.D. of Odylia Therapeutics profile picture

Luk Vandenberghe, PhD
Associate Professor, Harvard Medical School
Director, Grousbeck Gene Therapy Center
Massachusetts Eye and Ear

Eric A. Pierce, M.D., Ph.D., Director of the Inherited Retinal Disorders Service at Massachusetts Eye and Ear

Eric Pierce, MD, PhD
Director, Ocular Genomics Institute
Harvard Medical School
Director, Inherited Retinal Disorders Services
Massachusetts Eye and Ear

Scott Dorfman, CEO and co-founder of Odylia Therapeutics

Scott Dorfman, BBA
CEO, Odylia Therapeutics

John Fernandez, President of Massachusetts Eye and Ear

John Fernandez, MS
President and CEO,
Massachusetts Eye and Ear

Joan W. Miller, M.D., Chief of Ophthalmology at Massachusetts Eye and Ear and Massachusetts General Hospital

Joan Miller, MD
Chief of Ophthalmology,
Massachusetts Eye and Ear

Questions? We’re here to help!